Panel discussions
Capital raising and financing has become a major challenge for scale-up companies in today’s risk-off environment. Investors have started to scrutinise opportunities more holistically and credibility is achieved through profitability considerations and a viable scale-up plan; a pure growth case is no longer sufficient. What are the remaining opportunities for growth and exit? How can a path towards higher return on investment be clearly articulated to potential investors?
This panel will delve into the complexities of the current financing landscape, equipping biotech executives and entrepreneurs with the knowledge and tools needed to navigate the challenging financing landscape and achieve their objectives.
May 6, 09:00-09:45, room Singapore
| Name | Position | Institution |
|---|---|---|
| Liam Baynes | Partner - Audit & Assurance for Life Sciences | Deloitte |
| Enada Ismailaj | Senior Manager - Strategy, Risk and Transaction | Deloitte |
| Name | Position | Institution |
|---|---|---|
| Matthias Bodenstedt | CFO | Moonlake |
| Dr. Jannis Fischer | Co-Founder & CEO | Positrigo AG |
| Michael Hennig | CEO | leadXpro |
| Oleg Parosin | CEO | BioMedica |
| Dr. Jonas Zeller | CFO | Innomedica |
At Deloitte, we make an impact that matters. For over 175 years, we have worked with leaders around the world—from the Global 500® to private businesses—to help them build better futures. In the Biotech industry, innovation is blurring traditional boundaries. We are positioned to help you to drive your business forward—not only because we understand complex problems, but because we have the skills and multi-disciplinary solutions to help solve them. We go beyond talk—we do.
